Q32 Bio Inc. (QTTB)
QTTB · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Signal Snapshot
2
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
2 Phase 2
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. — Lancet (2026) PMID 42628554
- Alopecia Areata: Current and Emerging Therapies. — Drugs (2026) PMID 42616344
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Q32 Bio Inc..
Full QTTB Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.